Supplementary table 3 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
openalex（2023）
摘要
Establishing recommended phase II dose (RP2D) and dose limiting toxicities (DLTs)
更多查看译文
关键词
mdsc differentiation,all-trans
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要